Close Menu

NEW YORK – Following the announcement of a $60 million exclusive global license earlier this week, Veracyte is now gearing up to engage international markets using NanoString Technology's nCounter Flex platform. 

While Seattle-based NanoString retains the rights to commercialize the nCounter for research use applications, Veracyte will transition its current diagnostic and prognostic cancer assays onto the platform in order to reach a global audience. 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.